Drug intelligence / Profile preview

OAK-006

Development stage: Preclinical
Lead developer: Oakrum Pharma
Modality: Small Molecules
Administration: Oral

Overview

OAK-006 is a small molecule therapeutic candidate currently in the development pipeline of Oakrum Pharma. It is formulated for oral delivery as a capsule. As of the current reporting, Oakrum Pharma has not publicly disclosed the specific therapeutic indication, molecular target, or mechanism of action for this candidate. The company's focus on specialty and generic pharmaceuticals suggests that OAK-006 may represent a proprietary formulation or a complex generic product in early-stage development.

Beyond the preview

Go deeper on OAK-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OAK-006.

Explore the full profile